Literature DB >> 23393358

Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer.

Kazunori Otsuka1, Hiroo Imai, Hiroshi Soeda, Keigo Komine, Chikashi Ishioka, Hiroyuki Shibata.   

Abstract

Molecular-targeted therapies require the assessment of targets and their related molecules. Circulating tumour cells (CTCs) are considered a very good source of samples for these purposes. In this study, we applied a practical method for examining CTCs to evaluate the effects of chemotherapy on advanced colorectal cancer (CRC). Even in stage IV CRC, CTCs were detected in only 38.5% (n=5/13) of the cases. However, in cases where CTCs were detected, the change in the number of CTCs compared before and after chemotherapy appeared to be associated with the therapeutic outcome. Changes in the number of CTCs may be a good predictive biomarker. Problems with this method are yet to be resolved, including the detection rate and the stability of the sample source for subsequent molecular analysis.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23393358

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  8 in total

1.  Predictive Value of Circulating Tumor Cells in Prognosis of Stage III/IV Colorectal Cancer After Oxaliplatin-based First-line Chemotherapy.

Authors:  Jiazi Yu; John Zhang; Tao Peng; Zhenglei Fei; Liangbin Jin; Mian Yang
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

2.  High circulating tumor cell concentrations in a specific subtype of gastric cancer with diffuse bone metastasis at diagnosis.

Authors:  Kazuhiro Shimazu; Koji Fukuda; Taichi Yoshida; Masahiro Inoue; Hiroyuki Shibata
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

3.  Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients.

Authors:  Gennaro Galizia; Marica Gemei; Michele Orditura; Ciro Romano; Anna Zamboli; Paolo Castellano; Andrea Mabilia; Annamaria Auricchio; Ferdinando De Vita; Luigi Del Vecchio; Eva Lieto
Journal:  J Gastrointest Surg       Date:  2013-06-28       Impact factor: 3.452

4.  Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.

Authors:  Christina Leah B Kline; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-21

5.  Morphological differences between circulating tumor cells from prostate cancer patients and cultured prostate cancer cells.

Authors:  Sunyoung Park; Richard R Ang; Simon P Duffy; Jenny Bazov; Kim N Chi; Peter C Black; Hongshen Ma
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

6.  Circulating tumor cell count as a biomarker of a specific gastric cancer subgroup characterized by bone metastasis and/or disseminated intravascular coagulation - an early indicator of chemotherapeutic response.

Authors:  Masahiro Inoue; Kazunori Otsuka; Hiroyuki Shibata
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

7.  Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells.

Authors:  Virgílio Souza E Silva; Ludmilla Thomé Domingos Chinen; Emne A Abdallah; Aline Damascena; Jociana Paludo; Rubens Chojniak; Aldo Lourenço Abbade Dettino; Celso Abdon Lopes de Mello; Vanessa S Alves; Marcello F Fanelli
Journal:  Onco Targets Ther       Date:  2016-12-13       Impact factor: 4.147

8.  Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.

Authors:  Shihui Ma; Feihai Ling; Anping Gui; Shifeng Chen; Yanxiang Sun; Zhou Li
Journal:  Med Sci Monit       Date:  2017-10-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.